Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
NYSE:RCUS
Price:
17.77 USD
3.86%
Updated:
May 15, 2024
Arcus Biosciences Inc
Selling, General & Administrative
|
Arcus Biosciences Inc
Selling, General & Administrative Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Selling, General & Administrative
-$119m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$12.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$6.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-12%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-23%
|
See Also
What is Arcus Biosciences Inc's Selling, General & Administrative?
Selling, General & Administrative
-119m
USD
-119m
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Selling, General & Administrative amounts to -119m USD.
What is Arcus Biosciences Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-50%
-50%
Over the last year, the Selling, General & Administrative growth was -8%. The average annual Selling, General & Administrative growth rates for Arcus Biosciences Inc have been -32% over the past three years , -50% over the past five years .
You don't have any saved screeners yet
